RxDoctor Payments Data

Stephanie Boone, APRN

Primary Care · Harrogate, TNNPI 1932727112

Payments from drug & device makers

$1,101in general payments, 2019–2025

Across 37 payments — averaging $29.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$408
  • Lilly USA, LLC$223
  • AstraZeneca$198
  • GSK$176
  • Mirum Pharmaceuticals, Inc.$20
  • Pfizer$18
  • plus $59 from 4 others

What the payments were for

  • Food & beverage$1,101100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,101 in reported general payments places this provider in the 65th percentile of 189 primary care providers in Tennessee.

See all primary care providers in Tennessee

Medicare billing

Part B allowed, 2024
$10,598
Medicare patients
56
Services billed
227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide19$23,683
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$18,282
OzempicSemaglutide12$15,271
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$14,329
Albuterol Sulfate HfaAlbuterol Sulfate58$1,049
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen36$757
Fluticasone Propionate54$648
Tizanidine Hcl14$596
Atorvastatin Calcium58$558
Potassium Chloride28$533
Levothyroxine Sodium60$494
Esomeprazole Magnesium14$476
Omeprazole32$462
Gabapentin54$440
Montelukast Sodium43$392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$223$23,68319 claims
AstraZenecaBreztri Aerosphere$198$18,28221 claims
Novo NordiskOzempic$15$15,27112 claims
GSKTrelegy Ellipta$176$14,32918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 189 primary care providers in Tennessee.

Other primary care in Harrogate

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →